SBIR/STTR Research Award

Elastic biodegradable ureteral stent

Award identifier fa333841e1010a038896450c45042b961cf9c0d7b8b7af3e09b74d044a7aa678Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$100,000

Program and phase

SBIR · Phase I

Award year

2009

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
AKINA, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
WTBLC3LE13U1
Solicitation number
PHS2009-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): The objective of this Phase I study is to develop elastic, biodegradable ureteral stents that will degrade in the body within 2 weeks after a procedure. Current ureteral stents are made of non-degradable polymers and, unless they are permanent, have to be removed by second procedure, which requires further intervention on the patients. Biodegradable ureteral stents will not require a second surgical removal procedure. There are many surgical procedures that require the emplacement of a ureteral stent. The ureter is a tube that allows urine to flow from the kidney to the bladder. Ureteral stent emplacement is utilized in surgical procedures for ailments, such as kidney infections, or kidney stones. Commonly, the stent is used to provide temporary support for the ureter and to allow urine flow until the ureter heals sufficiently to maintain its own integrity and flow or to bypass ureteral obstruction. This process takes approximately 2 weeks, after which non-degradable stents must be removed by a second procedure. The proposed stent will degrade in 2 weeks eliminating the need for a second procedure. The two main properties to be optimized in this study are elasticity and degradation. Specific Aim 1 is to synthesize biodegradable polymers with good elasticity and degradation kinetics matching the applications of ureteral stents. These polymers will be formulated from macromonomers containing biodegradable portions and water-soluble portions in controlled amounts so as to maximize elasticity and have degradation occur with approximately 2 weeks. Specific Aim 2 is to design ureteral stent configuration to ensure degradation into small pieces, e.g., less than 2 mm, for easy removal from the ureter. This stent will be manufactured layer-by-layer by either electrospraying or spraying through an ultrasonic nozzle polymer solution onto a rotating mandrel. The innermost layer will be a rapidly degrading formulation, the middle layer will be a mixture of biological polymers, such as chitosan or alginate formulated in microbeads, and the outermost layer will be a slow degrading formulation capable of providing mechanical support during degradation. Pigtail coils will be formed on each end to ensure the stent remains in place. Successful completion of this Phase I study will demonstrate the feasibility of novel, elastic, biodegradable stents capable of degrading after 2 weeks eliminating the need for a second removal procedure. These stents will remain until sufficient healing has occurred and they are no longer necessary. The stent will be designed to have the same size and properties as currently existing stents so that currently existing catheter guide wires and techniques may be used for their emplacement. Phase II development will focus on creating a marketable prototype and animal studies. PUBLIC HEALTH RELEVANCE: The objective of this research is to generate elastic, biodegradable polymer-based ureteral stents for use in ureteral surgery. These stents will overcome problems associated with current technology by eliminating the need for a second surgery to remove the stent. This technology will improve patient convenience, reduce complications associated with a second removal procedure, and eliminate the cost for the stent removal procedure.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

7 SBIR/STTR records share this UEI (2007–2023). Reported award amounts total $2,191,331. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.